DCG(I) has come up with mandatory provisions for pharma companies to undergo stability tests for approval of drugs in India. Though it will raise the standard for quality of drugs in the global market, it will also have considerable impact on pharma company’s bottom line. Industry experts have a mixed bag of opinions
Bhavin Mehta, Director, Kilitch Drugs
Comments are closed.